← Drug database

Usrenty (ustekinumab)

BiosimilarAdditional monitoring
Region
🇪🇺 EU
Active substance
ustekinumab
Company
Biosimilar Collaborations Ireland Limited
Status
Authorised
Therapeutic area
Crohn Disease
CHMP opinion
Thu 24 Jul 2025
EU approval
Wed 17 Sep 2025
Designations
Biosimilar, Additional monitoring
Application
EMEA/H/C/006794
ATC
L04AC05
Official record
www.ema.europa.eu

Indication

Plaque psoriasis Usrenty is indicated for the treatment of moderate to severe plaque psoriasis in adults who failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapies including ciclosporin, methotrexate (MTX) or PUVA (psoralen and ultraviolet A). Paediatric plaque psoriasis Usrenty is indicated for the treatment of moderate to severe plaque psoriasis in children and adolescent patients from the age of 6 years and older, who are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies. Psoriatic arthritis (PsA) Usrenty, alone or in combination with MTX, is indicated for the treatment of active psoriatic arthritis in adult patients when the response to previous non-biological disease-modifying anti-rheumatic drug (DMARD) therapy has been inadequate.   Crohn’s Disease Usrenty is indicated for the treatment of adult patients with moderately to severely active Crohn’s disease who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a TNFα antagonist.

Regulatory milestones

No milestones recorded in the last year.

Same substance in other markets

Follow Usrenty

Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.

Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.